Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto

The present invention relates to compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the beta-3 adrenergic receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of a beta-3 adre...

Full description

Saved in:
Bibliographic Details
Main Authors Blackburn, Anthony C, Tran, Thuy-Anh, Nagura, Maiko, Do, Quyen-Quyen, Ullman, Brett
Format Patent
LanguageEnglish
Published 23.02.2021
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The present invention relates to compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the beta-3 adrenergic receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of a beta-3 adrenergic receptor-mediated disorder, such as, heart failure; cardiac performance in heart failure; mortality, reinfarction, and/or hospitalization in connection with heart failure; acute heart failure; acute decompensated heart failure; congestive heart failure; severe congestive heart failure; organ damage associated with heart failure (e.g., kidney damage or failure, heart valve problems, heart rhythm problems, and/or liver damage); heart failure due to left ventricular dysfunction; heart failure with normal ejection fraction; cardiovascular mortality following myocardial infarction; cardiovascular mortality in patients with left ventricular failure or left ventricular dysfunction; left ventricular failure; left ventricular dysfunction; class II heart failure using the New York Heart Association (NYHA) classification system; class III heart failure using the New York Heart Association (NYHA) classification system; class IV heart failure using the New York Heart Association (NYHA) classification system; LVEF<40% by radionuclide ventriculography; LVEF≤35% by echocardiography or ventricular contrast angiography; and conditions related thereto.
AbstractList The present invention relates to compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the beta-3 adrenergic receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of a beta-3 adrenergic receptor-mediated disorder, such as, heart failure; cardiac performance in heart failure; mortality, reinfarction, and/or hospitalization in connection with heart failure; acute heart failure; acute decompensated heart failure; congestive heart failure; severe congestive heart failure; organ damage associated with heart failure (e.g., kidney damage or failure, heart valve problems, heart rhythm problems, and/or liver damage); heart failure due to left ventricular dysfunction; heart failure with normal ejection fraction; cardiovascular mortality following myocardial infarction; cardiovascular mortality in patients with left ventricular failure or left ventricular dysfunction; left ventricular failure; left ventricular dysfunction; class II heart failure using the New York Heart Association (NYHA) classification system; class III heart failure using the New York Heart Association (NYHA) classification system; class IV heart failure using the New York Heart Association (NYHA) classification system; LVEF<40% by radionuclide ventriculography; LVEF≤35% by echocardiography or ventricular contrast angiography; and conditions related thereto.
Author Tran, Thuy-Anh
Blackburn, Anthony C
Nagura, Maiko
Ullman, Brett
Do, Quyen-Quyen
Author_xml – fullname: Blackburn, Anthony C
– fullname: Tran, Thuy-Anh
– fullname: Nagura, Maiko
– fullname: Do, Quyen-Quyen
– fullname: Ullman, Brett
BookMark eNqNjTsOwjAQRF1Awe8OywEikaRAtCAQDRVQRyYeQ6TgtdYbzo8jcQCqHY3evJ2bSeCAmYkXdkNvlSURe9IX6AG1RU3WCQLk2bUkaBEzQkOCH3ryOY6kCqy-EZRyEQWfHDsOo8h1icUhWwVZDzcOBMpLM_W2T1j97sKsT8fb4VwgcoMUbZu_anO_lptdtS2rel_V_zBfwFhFag
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
ExternalDocumentID US10927123B2
GroupedDBID EVB
ID FETCH-epo_espacenet_US10927123B23
IEDL.DBID EVB
IngestDate Fri Jul 19 13:00:07 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_US10927123B23
Notes Application Number: US202016872812
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210223&DB=EPODOC&CC=US&NR=10927123B2
ParticipantIDs epo_espacenet_US10927123B2
PublicationCentury 2000
PublicationDate 20210223
PublicationDateYYYYMMDD 2021-02-23
PublicationDate_xml – month: 02
  year: 2021
  text: 20210223
  day: 23
PublicationDecade 2020
PublicationYear 2021
RelatedCompanies Arena Pharmaceuticals, Inc
RelatedCompanies_xml – name: Arena Pharmaceuticals, Inc
Score 3.322129
Snippet The present invention relates to compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the beta-3 adrenergic...
SourceID epo
SourceType Open Access Repository
SubjectTerms CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Title Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210223&DB=EPODOC&locale=&CC=US&NR=10927123B2
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LS8NAEB5KFfWmVdH6YAXJbVGaNE0OQciLIvSBbaS3sptsQZFsyAP_vrNL2nrRW9hshs3AfDubzPcNwKPtqnbuXFCbiQ21bMYpc9wBzZhjmZw7Q4vpaoupPU6s19Vw1YHPLRdG64R-a3FEjKgU473WeF3sP2KFurayeuIfOCRf4qUXGu3pWJ9fTCP0vWg-C2eBEQResjCmb5jruoMRorSPcH2AabSjyv-id1-xUorfW0p8CodztJbXZ9AReQ-Og23ntR4cTdof3njZxl51DsVEZqrXliwrIjcEEzfCcY3UJEyxsUWJGEYQv0SBU0hTiU3zRTAl1TN39eQEB4pWtknmylDW6m9WRPNaRKYeKEUtL-AhjpbBmOLS1zs_rZPF_i3NS-jmMhdXQOwRApormBLOx-Qp44pc61qpmyphwvT5Gvp_2-n_d_MGTpTPNcPbvIVuXTbiDvfomt9r5_4AUgGXwQ
link.rule.ids 230,309,786,891,25585,76894
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fS8MwED7GFOebTkXnrwjSt6KsXbc8DGHtytR1G26TvZWkTUGRprQd_vteQrf5om8lTY_04L5c2vu-A7h3qGrnzoXpMJGYtsO4yXq0bcasZ1uc9zo209UWE2e0tF9WnVUNPjdcGK0T-q3FETGiIoz3UuN1tvuI5enayuKBf-CQfPIXfc-oTsf6_GIZ3qA_nE29qWu4bn85NyZvmOvSdhdReoBwvYcpNlU6-8P3gWKlZL-3FP8I9mdoLS2PoSbSJjTcTee1JhwE1Q9vvKxirziBLJCx6rUl84LIhGDiRjiu0bQIU2xskSOGEcQvkeEUsi5Esv4imJLqmdt6coIDWSXbJFNlKK70NwuieS0iVg_kopSncOcPF-7IxKWHWz-Fy_nuLa0zqKcyFedAnC4CGhVMCedj8hRzRa6ldkQjJUwYPV5A6287rf9u3kJjtAjG4fh58noJh8r_mu1tXUG9zNfiGvfrkt9oR_8AnXqatA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=Modulators+of+the+beta-3+adrenergic+receptor+useful+for+the+treatment+or+prevention+of+disorders+related+thereto&rft.inventor=Blackburn%2C+Anthony+C&rft.inventor=Tran%2C+Thuy-Anh&rft.inventor=Nagura%2C+Maiko&rft.inventor=Do%2C+Quyen-Quyen&rft.inventor=Ullman%2C+Brett&rft.date=2021-02-23&rft.externalDBID=B2&rft.externalDocID=US10927123B2